Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
J Clin Virol ; 53(4): 280-4, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22265827

RESUMO

BACKGROUND: About 100 serotypes of human rhinovirus (HRV), classified into two species, have been identified by 1990. Uncultivable HRV variants have recently been identified and designated a new species. Recent improved diagnosis has led to a re-appraisal of the clinical impact of HRV infections in lower respiratory diseases. OBJECTIVES: To characterise clinical features in hospitalised patients with positive HRV RNA detection and to determine the distribution of HRV species in respiratory infections diagnosed during the winter of 2009-2010. STUDY DESIGN: Prospective virus typing was conducted by sequencing the VP4/VP2 genomic regions, and clinical data were collected. RESULTS: Fifty-eight patients (for 63 respiratory specimens) were included. Phylogenetic analysis identified 52% of HRV species A, 6% of species B and 40% of species C, and revealed the co-circulation of 34 different HRV types during the study period. Three infants had successive infections with two or three different types. Five patients were admitted to an intensive care unit, four of them on arrival. Bronchiolitis, pneumonia and exacerbation of asthma were observed in 34/45 children. Pneumonia and severe exacerbation of chronic lung disease were observed in 8/13 adults, of whom 1, with immunocompromised status, died of multivisceral failure. CONCLUSIONS: This study underlines the diversity of co-circulating strains and the potential severity of clinical presentations associated with HRV infections.


Assuntos
Infecções por Picornaviridae/fisiopatologia , Infecções Respiratórias/fisiopatologia , Rhinovirus/genética , Rhinovirus/patogenicidade , Adolescente , Adulto , Idoso , Asma/epidemiologia , Asma/fisiopatologia , Bronquiolite Viral/epidemiologia , Bronquiolite Viral/fisiopatologia , Bronquiolite Viral/virologia , Criança , Pré-Escolar , Feminino , Genótipo , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Dados de Sequência Molecular , Filogenia , Infecções por Picornaviridae/epidemiologia , Infecções por Picornaviridae/virologia , Pneumonia Viral/epidemiologia , Pneumonia Viral/fisiopatologia , Pneumonia Viral/virologia , Estudos Prospectivos , RNA Viral/análise , Infecções Respiratórias/epidemiologia , Infecções Respiratórias/virologia , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Rhinovirus/classificação , Estações do Ano , Análise de Sequência de DNA , Adulto Jovem
2.
Presse Med ; 35(7-8): 1167-73, 2006.
Artigo em Francês | MEDLINE | ID: mdl-16840893

RESUMO

OBJECTIVES: To evaluate a strategy based on screening and isolation at admission to a department of infectious diseases during an epidemic of vancomycin-resistant Enterococcus (VRE) at the University Hospital of Clermont-Ferrand. METHODS: Systematic screening for VRE by anal swabs began on November 15, 2004. Patients were isolated on admission if (a) they had been hospitalized more than 24 h in an at-risk department of our hospital or (b) they had received a course of wide-spectrum antimicrobial therapy for longer than 48 h in the three months preceding admission. Patients hospitalized in our department were screened weekly if they were treated with wide-spectrum antibiotics, had a urinary catheter left in place for one week, or were neutropenic. RESULTS: Through May 15, 2005, 12 (3.5%) of 341 swabs were found to be positive for VRE: eight were detected on admission and four during hospitalization. In all, 81 patients were isolated on admission. A case-control study confirmed that the criteria for patient isolation were indeed risk factors for VRE. Isolation was well accepted when it was clearly explained. No new case has been detected since March 2005. CONCLUSION: An isolation strategy based on known risk factors for VRE with systematic screening on admission appears to be an effective way to control an outbreak of VRE, perhaps in part because it helps to keep the medical staff alert to this problem. Isolation is well tolerated as long as it is explained clearly.


Assuntos
Enterococcus/efeitos dos fármacos , Infecções por Bactérias Gram-Positivas/tratamento farmacológico , Infecções por Bactérias Gram-Positivas/transmissão , Programas de Rastreamento/métodos , Vancomicina/farmacologia , Vancomicina/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Farmacorresistência Bacteriana , Humanos , Pessoa de Meia-Idade , Fatores de Risco
3.
BMC Infect Dis ; 6: 115, 2006 Jul 17.
Artigo em Inglês | MEDLINE | ID: mdl-16846490

RESUMO

BACKGROUND: Lemierre's syndrome presents a classic clinical picture, the pathophysiology of which remains obscure. Attempts have been made to trace genetic predispositions that modify the host detection of pathogen or the resultant systemic reaction. CASE PRESENTATION: A 17-year old female, with no previous medical history, was admitted to the intensive care unit for septic shock, acute respiratory distress syndrome and Lemierre's syndrome. Her DNA was assayed for single nucleotide polymorphisms previously incriminated in the detection of the pathogen, the inflammatory response and the coagulation cascade. We observed functional variations in her Toll like 5 receptor (TLR 5) gene and two coagulation variations (Tissue Factor (TF) 603 and Plasminogen-Activator-Inhibitor-1 (PAI-1) 4G-4G homozygosity) associated with thrombotic events. CONCLUSION: The innate immune response and the prothrombogenic mutations could explain, at least in part, the symptoms of Lemierre's syndrome. Genomic study of several patients with Lemierre's syndrome may reveal its pathophysiology.


Assuntos
Infecções por Fusobacterium/genética , Tromboflebite/genética , Adolescente , Feminino , Infecções por Fusobacterium/tratamento farmacológico , Fusobacterium necrophorum , Humanos , Faringite/microbiologia , Inibidor 1 de Ativador de Plasminogênio/genética , Polimorfismo de Nucleotídeo Único , Síndrome do Desconforto Respiratório/microbiologia , Choque Séptico/microbiologia , Síndrome , Tromboflebite/microbiologia , Tromboplastina/genética , Receptor 5 Toll-Like/genética
4.
Reprod Nutr Dev ; 43(2): 203-14, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-12956319

RESUMO

We have examined the effect of a medroxyprogesterone therapy in HIV-infected patients under appropriate nutrition for anabolism. The experiments were performed on 12 men (mean age 40 y), HIV seropositive but free of any clinically active opportunistic infection for at least one month. The patients underwent a 2-week baseline diet period (1.2 g protein x kg(-1) body weight (BW) x d(-1)) and then a 5-week experimental period with again the baseline diet in conjunction with supplements including Tonexis HP (0.7 g protein x kg(-1) BW) x d(-1)), L-threonine (0.018 g x kg(-1) BW x d(-1)) and L-methionine (0.013 g x kg(-1) BW x d(-1)). Indeed HIV-infected patients showed deficiencies in these amino acids. They were randomly divided into groups I and II under double-blinded condition. Group II was given medroxyprogesterone acetate (0.4 g x d(-1)) during the last 3 weeks whereas group I received a placebo. All the patients significantly increased their body weight (P < 0.05) during the experimental periods. Those under medroxyprogesterone tended to show a higher but not significant weight gain (+3.1 +/- 1.0 kg in group II and +1.9 +/- 0.3 kg in group I). Blood free amino acids were used as rough indicators of amino acid utilization and were analyzed prior and during acute 150 min intravenous infusion of a complete glucose-amino acid mixture. This test was done before and at the end of the experimental periods. Basal essential blood free amino acids were similar in the two groups and did not change during the experimental period. Most essential amino acids increased following glucose-amino acid infusions. The incremental increase was of less magnitude after the experimental period than before when medroxyprogesterone was present (P < 0.05 for valine, leucine, lysine, threonine and methionine). This was not the case in the absence of the hormone. We concluded that medroxyprogesterone might improve the efficacy of an oral protein-rich nutritional support in HIV-infected patients.


Assuntos
Proteínas Alimentares/administração & dosagem , Infecções por HIV/terapia , Acetato de Medroxiprogesterona/uso terapêutico , Apoio Nutricional , Adulto , Aminoácidos/administração & dosagem , Aminoácidos/sangue , Glicemia/análise , Proteínas Sanguíneas/análise , Método Duplo-Cego , Glucose/administração & dosagem , Humanos , Insulina/sangue , Resistência à Insulina , Masculino , Placebos , Ureia/sangue , Aumento de Peso
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA